Trial Profile

Phase I/II Trial of Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 16 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bintrafusp alfa (Primary) ; PDS 0101 (Primary) ; PDS 0301 (Primary)
Indications Anal cancer; Cervical cancer; Head and neck cancer; Human papillomavirus infections; Lung cancer; Oesophageal cancer; Oropharyngeal cancer; Penile cancer; Rectal cancer; Solid tumours; Squamous cell cancer; Vulvovaginal cancer
Focus Therapeutic Use

Most Recent Events

26 Feb 2025 Results published in the PDS Biotechnology Corporation Media Release.
26 Feb 2025 According to a PDS Biotechnology Corporation media release, the results from this trial were published in the Journal of the American Medical Association (JAMA) Oncology.
15 Jul 2023 Planned End Date changed from 1 Jan 2024 to 1 Jul 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com